Windtree Therapeutics, Inc.
OTC: WINT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jed A. Latkin
- Employees
- 14
- Headquarters
- Warrington, United States
- IPO year
- 1995
- Market cap
- $539.3K
- Website
- https://windtreetx.com
Loading WINT…
Loading profile data…Frequently asked questions about WINT
What does Windtree Therapeutics, Inc. (WINT) do?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for ear...
Where does WINT trade?
Windtree Therapeutics, Inc. (WINT) trades on the Other OTC.
What sector is WINT in?
Windtree Therapeutics, Inc. (WINT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Windtree Therapeutics, Inc.?
Jed A. Latkin is the chief executive officer of Windtree Therapeutics, Inc. (WINT).
Where is Windtree Therapeutics, Inc. headquartered?
Windtree Therapeutics, Inc. is headquartered in United States.
Does WINT pay a dividend?
Windtree Therapeutics, Inc. (WINT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did WINT go public?
Windtree Therapeutics, Inc. (WINT) completed its initial public offering in 1995.